Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Epithalon vs GHK-Cu
Peptide Schedule Research TeamReviewed Aug 7, 202618 Citations
Epithalon and GHK-Cu are both filed under anti-aging, but their evidence comes from different places. Epithalon's telomere results come from cell cultures, and its few human studies measured melatonin and the retina. GHK-Cu's human data come from small trials of creams and gels on the skin.
A 2025 paper changed the conversation around this peptide. Al-Dulaimi and colleagues replicated epithalon's telomere elongation effect in human cell lines (PMID 40908429), confirming telomerase upregulation independent of Khavinson's lab for the first time. Epithalon (epitalon, molecular weight 390.35 Da) is a synthetic tetrapeptide modeled after epithalamin, a pineal gland extract. It activates telomerase, the enzyme that adds TTAGGG repeats to chromosome ends. Short telomeres push cells into senescence or death. Restoring telomerase activity, at least in theory, reverses that clock. The practical picture is more complicated. Seven of the papers sent to FDA to support compounding it described epithalamin, the pineal extract, not epithalon. FDA treats the two as different substances and found three human studies of epithalon itself (July 2026 briefing). FDA describes one of them as randomized and placebo-controlled (Ivko 2021). It was small: 40 women aged 40 to 50 took sublingual epithalon or placebo for 20 days. A urinary melatonin marker rose 1.7-fold on epithalon. The study reported no safety data and did not say whether it was blinded. A 2025 IJMS review (PMID 40141333) noted explicitly that safety information on this peptide is missing. Community use tells a different story. Hundreds of users across peptide forums run 10-day cycles twice per year and report rapid sleep improvement, typically by day 3 to 5. That effect operates through pineal melatonin normalization, a faster and better-understood mechanism than telomere extension. Deeper sleep, fewer awakenings, and improved morning energy are the most reproducible outcomes. The telomere claim itself is taken largely on faith since no practical at-home marker exists; telomere testing before and after multiple cycles is the only objective route, and single-measurement variability is large. Epithalon was on the FDA Category 2 list until its nominators withdrew it (FDA page current as of April 22, 2026), and PCAC discussed it on July 24, 2026. All current supply is research-grade.
View full guide →At least 4,000 human genes. That's how many GHK-Cu raises or lowers in gene expression data analyzed by Pickart's group (PMID 29986520, 26236730). The GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper(II), also written GHK:Cu or copper tripeptide-1) is a naturally occurring copper peptide found in human plasma, saliva, and urine. Plasma levels sit around 200 ng/mL at age 20 and drop to roughly 80 ng/mL by age 60. The mechanism is broad. GHK-Cu upregulates collagen I, III, and V synthesis, boosts elastin and decorin production, and recruits immune and endothelial cells to damaged tissue. The copper ion itself is required for enzymatic processes in wound remodeling. In 2024, Bian and colleagues confirmed anti-fibrotic activity in silicosis mice and found lower plasma GHK in silicosis patients (PMID 38879894). Its research now reaches past skin. In practice, two routes dominate. Topical formulations (1 to 3% concentration) have cosmetic safety data going back decades; small clinical trials (n = 41 to 71) showed improved skin density and fine line reduction. Injectable use (0.5 to 2 mg/day subcutaneous) has no published dose-finding trial in humans but has one of the largest community evidence bases of any anti-aging peptide. Reports across r/Peptides, r/Biohackers, and practitioner networks describe improved skin firmness by weeks four to six; sentiment runs at 4.2 out of 5. The honest limitation: all mechanistic data is in vitro or murine. Pro-angiogenic activity flagged by the NCI raises an unresolved theoretical oncology concern. GHK-Cu is classified as research-only and is not FDA-approved for any indication.
View full guide →At a Glance
| Attribute | ||
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| Safety Grade | B | B |
| Half-Life | ~30 minutes (plasma) | ~1 hour |
| Route | Subcutaneous or Intramuscular | Subcutaneous or Topical |
| Vial Sizes | 10 mg | 5 mg, 50 mg |
| Beginner Dose | 5 mg Daily | 1 mg Daily |
| Moderate Dose | 10 mg Daily | 2 mg Daily |
| Aggressive Dose | 10 mg Daily | 3 mg Daily |
| Dosing Source | Community | Community |
| Side Effects | The biggest concern with epithalon isn't a side effect you'll feel. It's a theoretical risk you can't observe. Telomerase reactivation is a hallmark of cancer cell immortalization. Khavinson's rodent studies actually showed reduced tumor rates with epithalon, but Al-Dulaimi's 2025 paper found ALT pathway activation in cancer cell lines (PMID 40908429). That's a new signal. Anyone with active cancer or a cancer history should treat this as a hard stop. A 2025 IJMS systematic overview (PMID 40141333) stated explicitly that "information regarding critical issues about this peptide's safety is missing." The total human safety database is small, uncontrolled, and comes almost entirely from one research group. Published side effects from Khavinson's cohort studies: none reported beyond injection site reactions. That's a limitation of the data, not proof of safety. Unblinded observational studies in elderly populations are not designed to catch adverse events with any rigor. Community-reported effects paint a more complete picture. Injection site redness is common and expected for subcutaneous peptide administration. Rotate between abdomen and deltoid over a 10-day cycle. Redness spreading beyond the immediate injection area or lasting more than 24 hours warrants stopping. Vivid dreams and occasionally nightmares are reported by a minority of users. This tracks with the melatonin mechanism; improved melatonin output alters REM sleep architecture. It usually settles within a few days. Dropping to 5 mg/day helps if dreams become disruptive. Daytime drowsiness can occur, particularly if you're stacking epithalon with exogenous melatonin, magnesium, GABA, or valerian. The combination over-sedates. Reduce the dose or shift injection earlier in the evening. Contraindications: pregnancy or breastfeeding, active cancer or cancer history, known hypersensitivity to any of the four amino acid components, autoimmune conditions (use with medical supervision only), and children or adolescents (no safety data). Immunosuppressant users need close monitoring since epithalon may modulate immune function. Anyone on chemotherapy or anti-telomerase agents (imetelstat, BIBR 1532) faces a direct mechanistic conflict. Stop immediately if any unexplained mass or growth appears. Discontinue if cancer is diagnosed at any point during use. Stop if sleep paradoxically worsens. Do not extend cycles beyond 20 days. | The most serious concern with GHK-Cu is its pro-angiogenic activity. The NCI flagged this years ago: a peptide that promotes new blood vessel formation could, in theory, support tumor vascularization. No human case has confirmed this, but no study has ruled it out either. Anyone with an active malignancy should not use GHK-Cu without oncologist clearance. Copper toxicity is the second concern worth taking seriously. Continuous long-term use without lab monitoring creates an accumulation risk. Wilson's disease, hemochromatosis, and any copper metabolism disorder are absolute contraindications. Symptoms of copper excess include nausea, metallic taste, and jaundice; if these appear, stop immediately and get serum copper checked. Published side effects in topical trials are mild. Skin irritation, redness, and occasional contact sensitivity at higher concentrations. The more interesting adverse pattern comes from the community: "copper uglies." This is paradoxical skin worsening (sagging, accelerated wrinkling) caused by MMP-1 matrix metalloproteinase upregulation outpacing collagen synthesis. It happens most often with topical overuse or aggressive post-microneedling application. The fix is simple: drop to 1% concentration and wait 48 to 72 hours after microneedling before applying. Injectable side effects are dominated by injection site reactions. Burning and stinging from the copper ions is the number one complaint in community threads. Diluting with more bacteriostatic water, using a 31-gauge needle, and applying a cold compress for 60 seconds post-injection helps. Site rotation matters; no location should get more than one injection per week. Poor rotation leads to lipodystrophy (localized fat atrophy), which is harder to reverse than it sounds. At doses above 1.5 mg/day, some users report nausea and metallic taste. These are dose-dependent and resolve with reduction. Reconstituted stability is limited to two to three weeks refrigerated. Potency drops 15 to 30% by week four according to community tracking. The mcg versus mg calculation error is a real hazard for beginners; GHK-Cu vials are labeled in mg but doses are discussed in mcg. 1 mg equals 1,000 mcg. Getting this wrong by a factor of 1,000 is not theoretical; it's the most common beginner mistake in the community. Contraindications: Wilson's disease or copper metabolism disorders. Known hypersensitivity to GHK-Cu or copper compounds. Pregnancy or breastfeeding (no safety data). Hemochromatosis. Active malignancy without oncologist clearance. Severe kidney or liver dysfunction. Drug interactions: copper-chelating agents (penicillamine, trientine) reduce bioavailability by 60 to 80%. Zinc above 50 mg/day competes at copper transport sites. High-concentration topical vitamin C (15%+) chelates copper; separate application by two or more hours. Immunosuppressants may interact with the healing response; consult a prescriber. |
Key Differences
Epithalon, which FDA spells epitalon, is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly). It was modeled on epithalamin, a cattle pineal extract, and FDA treats the two as different substances (FDA epitalon briefing). GHK-Cu is a three-amino-acid peptide bound to copper and found in human plasma [7].
The telomere claim is a cell-culture finding. In cultures of telomerase-negative human fetal fibroblasts, epithalon switched on telomerase and lengthened telomeres [1]. A 2025 study from a UK lab outside Khavinson's group saw telomeres lengthen in normal human cells in culture too [2].
That 2025 study also tested breast cancer cell lines. There, telomeres grew through a separate route, ALT (alternative lengthening of telomeres), which the authors found specific to the cancer cells [2].
FDA's 2026 review found three human studies of epithalon itself, and none measured telomeres. Two gave it sublingually, under the tongue. The third gave it by parabulbar injection, beside the eyeball, in retinitis pigmentosa (FDA epitalon briefing).
The study FDA describes as placebo-controlled split 40 women aged 40 to 50 with low melatonin output between epithalon and placebo (FDA epitalon briefing). Treatment ran 20 days, at 0.5 mg a day under the tongue. Urinary 6-sulfatoxymelatonin, a melatonin marker, rose 1.7-fold on epithalon [3]. The study didn't measure sleep, report safety data or say whether it was blinded (FDA epitalon briefing).
FDA describes this study as randomized and placebo-controlled, while noting its small size and short duration (FDA epitalon briefing).
Several older Russian human studies used epithalamin, the pineal extract, rather than epithalon. Seven of the papers the nominators sent FDA were about epithalamin (FDA epitalon briefing). One followed 266 older adults for 6 to 8 years and reported 1.6- to 1.8-fold lower mortality with epithalamin than in controls [4]. PubMed indexes it as a randomized trial, but its abstract doesn't say how people were assigned to groups.
The retinitis pigmentosa report, from 2002, described a positive effect in 90% of cases, with no patient count in its abstract [5]. An FDA orphan drug designation for epithalon in that condition, granted in 2010, was withdrawn or revoked in 2016 (FDA epitalon briefing).
The mouse cancer data look favorable but thin. FDA says three female-mouse studies found epithalon suppressed spontaneous tumors (FDA epitalon briefing). In one, 54 mice per group got injections on 5 days a month, and average lifespan didn't change. Maximum lifespan rose 12.3% and leukemia fell 6-fold, while total tumor rates didn't change [6]. FDA judged these studies too limited to show whether epithalon could cause cancer, citing one dose, female mice only and short exposure (FDA epitalon briefing).
FDA's worry is the mechanism itself. Epithalon activates telomerase and lengthens telomeres in cells, and longer telomeres are generally associated with higher cancer risk (FDA epitalon briefing). Both profiles flag active cancer as a contraindication, and epithalon's also lists a past cancer.
GHK-Cu's collagen effect is a lab finding too. It raised collagen synthesis in fibroblast cultures, peaking at a nanomolar concentration [7]. Pickart's group counts at least 4,000 human genes that GHK switches up or down [8]. Those gene data come from the Connectivity Map, whose profiles were measured in five cancer cell lines, not in people [9].
GHK-Cu's human data come from skin products. In diabetic foot ulcers on the sole, a GHK-Cu gel closed a median 98.5% of ulcer area vs 60.8% on an inactive gel [10]. In a trial of 86 people with venous stasis ulcers, a 0.4% tripeptide-copper cream did no better than placebo [11].
The best-known cosmetic studies applied GHK-Cu creams for 12 weeks in 71 and 41 women. They reported denser skin and fewer fine lines, and both are cited from 2002 dermatology meeting proceedings [9]. A 2025 review still found a "surprising absence" of clinical studies of GHK-Cu in wrinkle products [12].
Community schedules differ. Epithalon runs in short courses of 5 to 10 mg a day for 10 to 20 days, then 4 to 6 months off (community reports). FDA found clinic websites listing the same 5 to 10 mg a day (FDA epitalon briefing). Injected GHK-Cu runs 1 to 3 mg a day for 4 to 8 weeks, and topical products are used without breaks (community reports). The same reports call 1 to 2 mg a day of injected GHK-Cu typical and note nausea above 1.5 mg a day.
No trial has set an injected dose for either peptide. The placebo-controlled epithalon study used 0.5 mg a day under the tongue, 10 to 20 times less than community injections.
Neither has an FDA approval. FDA found no approved epitalon product in the US, Canada, Australia, the UK or the EU (FDA epitalon briefing). Drugs@FDA lists no approved drug containing GHK-Cu (openFDA search, October 15, 2026).
Epithalon and injectable GHK-Cu sat in FDA's compounding category 2 until their nominators withdrew them (FDA category 2 page). FDA's 2026 briefing proposed not adding epithalon to the 503A bulks list, and its advisory committee discussed it on July 24, 2026. FDA has posted no minutes, and 21 CFR 216.23 lists neither peptide.
Non-injectable GHK-Cu was back on FDA's category 1, substances under evaluation, by May 14, 2026. FDA plans to consult its advisory committee on GHK-Cu before the end of February 2027 (FDA 503A categories list). WADA's 2026 list names neither peptide. Its S0 class prohibits any pharmacological substance outside the list's other classes that lacks current government approval for human therapeutic use (WADA 2026 list).
When to Choose Epithalon
Better sleep is the aim and community reports are enough for you (users describe it by days 3 to 5; FDA found no sleep study)
Short courses suit you better than daily use (community schedule: 10 to 20 days on, 4 to 6 months off)
The telomere idea interests you, knowing the evidence is from cell cultures [1]
When to Choose GHK-Cu
Your goal is skin, and a cream or gel suits you (the human trials tested topical products)
Human wound-healing data matter to you (a gel helped diabetic foot ulcers; a copper cream failed in venous ulcers)[10][11]
You want something for daily use rather than short courses (community reports use topical GHK-Cu without breaks)
Verdict
No study compares them, and their evidence sits at different levels. GHK-Cu has small human trials of skin products, with one positive trial in diabetic foot ulcers [10] and mixed results elsewhere. Epithalon's telomere effect is a cell-culture finding [1]. Its three human studies measured melatonin, circadian genes and the retina, not aging (FDA epitalon briefing). Community reports favor epithalon for sleep and GHK-Cu for skin.
Research peptides with both sides of the evidence.
Published studies and community reports, side by side, for 150+ peptides. Save the ones you are weighing and see when anything changes.
Can You Stack Epithalon + GHK-Cu?
Community anti-aging stacks often pair them, epithalon in short courses and GHK-Cu daily or on the skin. No study has tested the two together; a ClinicalTrials.gov search on October 15, 2026, found no registered trial of the pair. Different proposed mechanisms don't show that the combination adds benefit or is safe.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.
Related Comparisons
Related Guides & Stacks
Peptide Schedule Research TeamReviewed Aug 7, 202618 Citations
References
- [1]Epithalon induces telomerase activity and telomere elongation in telomerase-negative human fetal fibroblast cultures (Khavinson et al., Bull Exp Biol Med 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Epitalon and telomere length in normal human cells and breast cancer cell lines: telomerase in normal cells, ALT in cancer cells (Al-Dulaimi et al., Biogerontology 2025; figures corrected November 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]AEDG peptide (epitalon), urinary 6-sulfatoxymelatonin and circadian gene expression in people with reduced melatonin output, in Russian (Ivko et al., Adv Gerontol 2020) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Thymalin and epithalamin, thymus and pineal extracts, in 266 older adults over 6 to 8 years (Khavinson and Morozov, Neuro Endocrinol Lett 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Epitalon in Campbell rats and in patients with retinitis pigmentosa (Khavinson et al., Neuro Endocrinol Lett 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Epitalon, biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice (Anisimov et al., Biogerontology 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [7]GHK-Cu stimulates collagen synthesis in fibroblast cultures (Maquart et al., FEBS Lett 1988) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration, review (Pickart et al., Biomed Res Int 2015) (opens in a new tab)PubMed (opens in a new tab)Review
- [9]Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data, review (Pickart and Margolina, Int J Mol Sci 2018) (opens in a new tab)PubMed (opens in a new tab)Review
- [10]Topical GHK-Cu gel vs vehicle in diabetic neuropathic foot ulcers, multicenter randomized evaluator-blinded trial (Mulder et al., Wound Repair Regen 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [11]Silver sulfadiazine vs a 0.4% tripeptide-copper cream vs placebo in 86 patients with venous stasis ulcers (Bishop et al., J Vasc Surg 1992) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [12]Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective, review (Mortazavi et al., BioImpacts 2025) (opens in a new tab)PubMed (opens in a new tab)Review
Additional References
- FDA briefing document: epitalon-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (proposes not adding them to the 503A bulks list) (opens in a new tab)FDA Label
- FDA: bulk drug substances in compounding that may present significant safety risks, category 2 and nominated-but-withdrawn lists (current as of April 22, 2026) (opens in a new tab)FDA Label
- FDA: bulk drug substances nominated for 503A compounding, categories 1 to 3 (updated May 14, 2026; non-injectable GHK-Cu back in category 1) (opens in a new tab)FDA Label
- FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page (non-binding recommendations; no minutes posted as of October 15, 2026) (opens in a new tab)FDA Label
- 21 CFR 216.23: bulk drug substances that can be used in 503A compounding (eCFR, current through October 13, 2026; last amended 2019) (opens in a new tab)FDA Label
- World Anti-Doping Agency, 2026 Prohibited List: BPC-157 under S0; thymosin beta-4 and TB-500 under S2.3; CJC-1295, sermorelin and ipamorelin under S2.2.4; prohibited at all times (opens in a new tab)Review